These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23090418)

  • 21. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
    Kale MA; Sonwane GM
    Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation.
    Ahmed MF; Santali EY; El-Haggar R
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.
    He Q; Han C; Li G; Guo H; Wang Y; Hu Y; Lin Z; Wang Y
    Comput Biol Chem; 2020 Oct; 88():107328. PubMed ID: 32688011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
    Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
    Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR.
    El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, Synthesis, Biological Evaluation, and Molecular Modeling of 2-Difluoromethylbenzimidazole Derivatives as Potential PI3Kα Inhibitors.
    Wang X; Zhang M; Zhu R; Wu Z; Wu F; Wang Z; Yu Y
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of novel FLT-3 inhibitors based on dual-layer 3D-QSAR model and fragment-based compounds in silico.
    Shih KC; Lin CY; Chi HC; Hwang CS; Chen TS; Tang CY; Hsiao NW
    J Chem Inf Model; 2012 Jan; 52(1):146-55. PubMed ID: 22142286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
    Davis GD; Vasanthi AH
    Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. de novo design and synthesis of N-benzylanilines as new candidates for VEGFR tyrosine kinase inhibitors.
    Uno M; Ban HS; Nabeyama W; Nakamura H
    Org Biomol Chem; 2008 Mar; 6(6):979-81. PubMed ID: 18327319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring novel KDR inhibitors based on pharmaco-informatics methodology.
    Kar RK; Suryadevara P; Sahoo BR; Sahoo GC; Dikhit MR; Das P
    SAR QSAR Environ Res; 2013; 24(3):215-34. PubMed ID: 23437769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
    Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
    Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach.
    Liu YZ; Wang XL; Wang XY; Yu RL; Liu DQ; Kang CM
    J Mol Model; 2016 Sep; 22(9):222. PubMed ID: 27558799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
    Assefa H; Kamath S; Buolamwini JK
    J Comput Aided Mol Des; 2003 Aug; 17(8):475-93. PubMed ID: 14703120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
    Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
    Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3D-QSAR and molecular docking studies of 4-anilinoquinazoline derivatives: a rational approach to anticancer drug design.
    Nandi S; Bagchi MC
    Mol Divers; 2010 Feb; 14(1):27-38. PubMed ID: 19330460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A combined 3D-QSAR and molecular docking strategy to understand the binding mechanism of (V600E)B-RAF inhibitors.
    Ul-Haq Z; Mahmood U; Reza S
    Mol Divers; 2012 Nov; 16(4):771-85. PubMed ID: 23054531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
    Shi L; Wu TT; Wang Z; Xue JY; Xu YG
    Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-Activity Relationship Studies on VEGFR2 Tyrosine Kinase Inhibitors for Identification of Potential Natural Anticancer Compounds.
    Verma M; Sarfraz A; Hasan I; Vasudev PG; Khan F
    Med Chem; 2024; 20(6):646-661. PubMed ID: 38299297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Searching for Potential Novel BCR-ABL Tyrosine Kinase Inhibitors Through G-QSAR and Docking Studies of Some Novel 2-Phenazinamine Derivatives.
    Kale M; Sonwane G; Choudhari Y
    Curr Comput Aided Drug Des; 2020; 16(5):501-510. PubMed ID: 30345925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.